9-(4-Hydroxybutyl)adenine (10) was obtained by reaction of adenine with 4-[(2-tetrahydropyran-2-yl)oxy]butyl chloride (7) in the presence of DBU. 8-Bromo-9-(4-hydroxybutyl)adenine (13) was prepared by bromination of 10 or by alkylation of 8-bromoadenine (11) with 4-bromoethyl acetate followed by methanolysis. Tosylation of compound 13 afforded the 4-tosyloxy derivative 15 which gave on heating with methylamine or cyclopropylamine 6-methyl- (17a) or 6-cyclopropyl-7,8,9,10-tetrahydro-6H-[1,3]diazepino[1,2-e]purin-4-amine (17b), while the reaction with hydrazine afforded 7,8,9,10-tetrahydro-6H-[1,3]diazepino[1,2-e]purine-4,6-diamine (17d). Treatment of compound 13 with thionyl chloride gave 9-(4-chlorobutyl)-8-chloroadenine (18) as the main product which was transformed to 17b, 6-propyl-7,8,9,10-tetrahydro-6H-[1,3]diazepino[1,2-e]purin-4-amine (17c) or 7,8,9,10-tetrahydro-6H-[1,3]diazepino[1,2-e]purin-4-amine (17e) by reaction with cyclopropylamine, propylamine or ammonia, respectively. Compound 17e was quite stable both in acid and alkaline solutions, at room temperature or at 90 °C. Compound 13 was converted to 9-(4-hydroxybutyl)-8-methylaminoadenine (19) by reaction with methylamine. Compound 19 failed to undergo intramolecular cyclization to diazepine 17a on treatment with diphenyl carbonate, bis(4-nitrophenyl) carbonate or 1,1'-carbonyldiimidazole.
9-(4-羟基丁基)腺嘌呤(
10)是通过
腺嘌呤与4-[(2-
四氢呋喃-2-基)氧基]丁基
氯化物(
7)在
DBU存在下反应得到的。8-
溴-
9-(4-羟基丁基)腺嘌呤(
13)通过
10的
溴化或
8-溴腺嘌呤(
11)与4-
溴乙酸乙酯烷基化后随后进行
甲醇解得到。化合物
13的对
甲苯磺酰化得到4-对
甲苯磺酰氧基衍
生物15,加热与甲基胺或
环丙胺反应得到6-甲基-(
17a)或6-环丙基-7,8,9,10-四氢-6
H-[1,3]二氮杂
吡咯[1,2-
e]
嘌呤-4-胺(
17b),而与
肼反应得到7,8,9,10-四氢-6
H-[1,3]二氮杂
吡咯[1,2-
e]
嘌呤-4,6-二胺(
17d)。化合物
13与
氯化亚砜反应得到9-(4-
氯丁基)-
8-氯腺嘌呤(
18)作为主要产物,经转化得到
17b,6-丙基-7,8,9,10-四氢-6
H-[1,3]二氮杂
吡咯[1,2-
e]
嘌呤-4-胺(
17c)或7,8,9,10-四氢-6
H-[1,3]二氮杂
吡咯[1,2-
e]
嘌呤-4-胺(
17e),分别与
环丙胺、
丙胺或
氨反应。化合物
17e在酸性和碱性溶液中,在室温或90°C下都相当稳定。化合物
13通过与甲基胺反应转化为9-(
4-羟基丁基)-8-甲基
氨基
腺嘌呤(
19)。化合物
19在与二
苯基碳酸酯、双(4-
硝基苯基)
碳酸酯或1,1'-羰基二
咪唑处理时未能发生分子内环化反应形成二氮杂
吡咯17a。